BBO 10203
Alternative Names: BBO-10203; PI3K alpha:RAS breaker - BridgeBio PharmaLatest Information Update: 19 Jun 2025
At a glance
- Originator BridgeBio Pharma
- Developer BridgeBio Oncology Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors; Ras signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 15 Jun 2025 Pharmacodynamics data from a preclinical trial in Solid tumours released by BridgeBio Oncology Therapeutics
- 10 Dec 2024 Pharmacodynamics data from preclinical studies in breast cancer presented at the 47th Annual San Antonio Breast Cancer Symposium (SABCS-2024)
- 23 Oct 2024 Pharmacodynamics and adverse events data from preclinical trials in Solid tumours presented at 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)